These clinical observations combined with reports that PR antagonists inhibit growth of breast tumors expressing higher levels of PRA [17, 44, 55], a PR isoform associated with poor survival outcomes (Figure 5A), motivated us to study the anti-tumor activity of PR antagonists, alone and in combination with tamoxifen. This evidence concerns the gene PGR and neoplasm.